Introduction {#s1}
============

Development of AKI has been consistently associated with a higher mortality rate in acute myocardial infarction (AMI) patients [@pone.0069998-Bruetto1]--[@pone.0069998-Amin2]. However, the lack of a uniform standardization for the diagnosis of AKI led to conflicting epidemiological data, troubling the advancement in the management of this important syndrome [@pone.0069998-Ostermann1].

Three new classification systems were recently developed for diagnosing acute kidney injury (AKI). The first, Risk, Injury, Failure, Loss, and End-stage kidney disease (RIFLE) [@pone.0069998-Bellomo1] was developed by the Acute Dialysis Quality Initiative group. RIFLE is graded in increasing levels of severity. The first level, Risk, is defined as an abrupt (within 1--7 days) and sustained (\>24 h) serum creatinine (SCr) increase to ≥1.5 times the baseline SCr, a glomerular filtration rate (GFR) decrease \>25% from the baseline GFR, or a urine output \<0.5 mL/kg/h for \>6 h.

The second classification was developed by the Acute Kidney Injury Network (AKIN) [@pone.0069998-Mehta1]. It is also graded in increasing levels of severity (AKIN 1 to AKIN 3) and uses the concept of small changes in SCr over a short period of time. The first level, AKIN 1, is defined as a SCr increase ≥0.3 mg/dL or ≥1.5-fold compared with the baseline in a time window of 48 h or a urine output \<0.5 mL/kg/h for \>6 h.

The third and latest classification was developed by the Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group for their freshly launched KDIGO Clinical Practice for Acute Kidney Injury [@pone.0069998-Kidney1]. This definition is a wider combination from RIFLE and AKIN criteria and defined AKI as an increase in SCr by ≥0.3 mg/dL within 48 hours or an increase in SCr to ≥1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or an urine volume \<0.5 mL/kg/h for 6 hours. The combined use of small absolute and relatives increases in SCr in the KDIGO criteria may potentially make it more sensitive than RIFLE criteria. The new KDIGO criteria were not yet validated in AMI patients, and there are no data comparing AKI incidence and mortality defined by RIFLE and KDIGO after an AMI.

The aim of this study was to compare the incidence and the early (30-days) and late (1-year) mortality of AKI patients diagnosed by RIFLE and KDIGO criteria after ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI).

Methods {#s2}
=======

Ethics Statement {#s2a}
----------------

This protocol was approved by the Institutional Ethics Committee ("Comitê de Ética em Pesquisa em Seres Humanos da Faculdade de Medicina de Sao José do Rio Preto", Sao José do Rio Preto, Brazil, process 0040/2008), which agreed that informed consent was not necessary because of the purely observational nature of this study.

Diagnostic Criteria for AKI {#s2b}
---------------------------

AKI was diagnosed and staged using the RIFLE and KDIGO SCr criteria ([Table 1](#pone-0069998-t001){ref-type="table"}). GFR and urinary output criteria were not used for AKI diagnosis and staging in this study.

10.1371/journal.pone.0069998.t001

###### Serum creatinine criteria for defining and staging AKI[\*](#nt102){ref-type="table-fn"}.

![](pone.0069998.t001){#pone-0069998-t001-1}

  Stage                                                                                             Criteria
  --------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  RIFLE[†](#nt103){ref-type="table-fn"}   
  Risk                                                                                       SCr×1.5 versus baseline
  Injury                                                                                      SCr×2 versus baseline
  Failure                                                           SCr×3 versus baseline, or SCr≥4.0 mg/dL with an acute increase≥0.5 mg/dL
  KDIGO[†](#nt103){ref-type="table-fn"}   
  1                                                                     SCr increase 1.5--1.9 times baseline or ≥0.3 mg/dL (≥26.5 µmol/L)
  2                                                                                   SCr increase 2.0--2.9 times baseline
  3                                        SCr increase 3.0 times baseline or increase in SCr to ≥4.0 mg/dL (≥353.6 µmol/L) or initiation of renal replacement therapy

AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; SCr, serum creatinine. KDIGO, Kidney Disease: Improving Global Outcomes.

Modified from references [@pone.0069998-Bellomo1], [@pone.0069998-Kidney1].

Only the SCr criteria were used to diagnose and stage AKI and therefore glomerular filtration rate and urinary output criteria were omitted.

Patients {#s2c}
--------

This is a single center observational prospective cohort study. In total, 1,253 consecutive patients (October 2004 to December 2009) who were diagnosed as acute STEMI or NSTEMI [@pone.0069998-Thygesen1] were assessed in a prospective database on thoracic pain. Patients were included if ≥18 years-old, hospitalization \>48 h and had at least two SCr measurements in the first 7 days of hospitalization. Only the first hospital admission was considered if a patient had more than one hospitalization for AMI during the study period. Reasons for exclusion are shown in [figure 1](#pone-0069998-g001){ref-type="fig"}.

![Flow chart showing the total cohort, excluded patients and stratification by AKI severity grade according to the AKI criteria used (KDIGO or RIFLE).\
AMI, acute myocardial infarction; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.](pone.0069998.g001){#pone-0069998-g001}

The final studied cohort was composed of 1,050 subjects assessed by RIFLE and KDIGO criteria ([Figure 1](#pone-0069998-g001){ref-type="fig"}).

Creatinine Measurements and GFR Calculation {#s2d}
-------------------------------------------

The Jaffé colorimetric method (ADVIATM 1650, Bayer, Germany) was used for the SCr measurements. The SCr was measured on hospital admission, daily during the intensive care unit stay and thereafter as needed.

The estimated GFR (eGFR) was calculated by the Modification of Diet in Renal Disease formula (MDRD) [@pone.0069998-Levey1].

Systolic Left Ventricular Function (LVF) Measurements {#s2e}
-----------------------------------------------------

The systolic LVF (classified as normal, mild, moderate or severe dysfunction) [@pone.0069998-Cheitlin1] was assessed by echocardiography, as needed, in 85.7% (900) of the patients.

Outcomes {#s2f}
--------

The primary end point was death from any cause at 30 days and at the 1-year follow-up for those patients who survived after 30 days. Events occurring after one year were censored on day 365. The follow-up after discharge was obtained by reviewing electronic hospital system records, mail, or telephone contact.

Statistical Analysis {#s2g}
--------------------

The baseline characteristics (presented as medians with interquartile ranges) were compared via the t-test, Mann-Whitney test or Kruskal-Wallis test followed by the Dunn post-test for continuous variables. Categorical variables (presented as numbers and percentages) were compared by χ^2^ statistics or Fisher's exact test.

Event-free survival curves were estimated by the Kaplan-Meier method, and the curves were compared with the log-rank test in univariate analyses. Multivariate Cox proportional hazards analyses were used to assess the relationship between AKI and mortality in the first 30 days and at the 1-year follow-up, adjusting for those variables with p\<0.15 in the univariate analysis for mortality in each period and considered clinically important to be controlled. The proportional hazards test and the plotted cumulative survival estimate after the ln (-ln) transformation suggested that the hazards of these variables were proportional for the period analyzed.

For Cox analyses at 30 days the model was adjusted for age (reference \<65 years), gender (reference female), admission eGFR (reference ≥60 mL/min/1.73 m^2^), Killip class (reference ≤I at admission), systolic blood pressure (SBP) (reference ≥100 mmHg on admission), heart rate (HR) (reference ≤100 beats/min on admission), creatine phosphokinase (CPK-MB) and admission glycemia (continuous). The model was also adjusted for diabetes history, extracardiac vascular disease (EVD) history, clopidogrel use during hospitalization, use of diuretics, coronary angiography during hospitalization, reperfusion therapy with primary percutaneous coronary intervention (PCI) for STEMI, any type of revascularization with either PCI or coronary artery bypass graft (CABG) performed during hospitalization, reinfarction and severe systolic left ventricular dysfunction (LVD). For these variables, the reference was their absence or presence.

The multivariate Cox analysis at 1-year included all patients who survived for 30 days after AMI, with censoring at 365 days. The controlling variables were the same as those included at mortality at 30 days evaluation, except for gender, SBP\<100 mmHg, CPK-MB and reinfarction which did not meet the selection criteria (p\>0.15 in the univariate analysis) and for history of hypertension and prior use of angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), which were also included (p\<0.15 in the univariate analysis).

Differences were considered statistically significant by a two-tailed p\<0.05 or based on a 95% confidence interval (CI). Analyses were performed with SPSS statistical software (version 15.0, Chicago, IL, USA).

Results {#s3}
=======

Study Population Characteristics {#s3a}
--------------------------------

The clinical characteristics of the general population are shown in [Table 2](#pone-0069998-t002){ref-type="table"}. The median for the hospitalization time was 7 (interquartile range: 4--12) days. Reinfarction occurred in 5.1% and dialysis was performed in 2.1% of the entire analyzed cohort. The in-hospital mortality rate was 13%.

10.1371/journal.pone.0069998.t002

###### Baseline clinical characteristics and medical therapy during hospitalization.
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  Characteristics                                                                 (n = 1050 )
  ------------------------------------------------------------ -------------------------------------------------
  Age (y)                                                        65 (55--74)[\*](#nt105){ref-type="table-fn"}
  Male                                                                            674 (64.2%)
  White                                                                           969 (92.3%)
  Hypertension history                                                            730 (69.5%)
  Current smoking                                                                  389 (37%)
  Diabetes history                                                                261 (24.9%)
  Hyperlipidemia history                                                          236 (22.5%)
  EVD history                                                                      80 (7.6%)
  Previous PCI[†](#nt106){ref-type="table-fn"}                                     93 (8.9%)
  Previous CABG[†](#nt106){ref-type="table-fn"}                                    88 (8.4%)
  Prior CAD (stenosis \>50%)[†](#nt106){ref-type="table-fn"}                      151 (14.4%)
  Previous infarction[†](#nt106){ref-type="table-fn"}                             153 (14.6%)
  ACEs/ARBs prior use [‡](#nt107){ref-type="table-fn"}                            443 (42.6%)
  STEMI                                                                           518 (49.3%)
  Killip classes II--IV[§](#nt108){ref-type="table-fn"}                           87 (19.3%)
  Anterior wall infarction[§](#nt108){ref-type="table-fn"}                        279 (53.9%)
  SBP\<100 mmHg[†](#nt106){ref-type="table-fn"}                                    67 (6.4%)
  Weight (kg)                                                    70 (62--80)[\*](#nt105){ref-type="table-fn"}
  HR \>100 (beats/min)                                                            165 (15.7%)
  CK-MB (IU/L)                                                   85 (39--187)[\*](#nt105){ref-type="table-fn"}
  Admission SCr (mg/dL)                                         1.2 (1.0--1.5)[\*](#nt105){ref-type="table-fn"}
  Admission eGFR (mL/min/1.73 m^2^)                             61 (47--78.6)[\*](#nt105){ref-type="table-fn"}
  Admission glycemia (mg/dL)                                    123 (100--176)[\*](#nt105){ref-type="table-fn"}
  Medical therapy and invasive procedures                      
  Aspirin                                                                        1043 (99.3%)
  Clopidogrel                                                                      893 (85%)
  β-Blockers                                                                      985 (93.8%)
  ACEIs or ARBs                                                                   1019 (97%)
  Statins                                                                         973 (92.7%)
  Coronary angiogram                                                              858 (81.7%)
  Any PCI[\|\|](#nt109){ref-type="table-fn"}                                      531 (50.6%)
  CABG                                                                             66 (6.3%)
  Reperfusion therapy[§](#nt108){ref-type="table-fn"}          
  Primary PCI                                                                     270 (52.1%)
  Thrombolytics                                                                    150 (29%)

Continuous variables are presented as the medians (with interquartile ranges), and categorical variables are presented as numbers and percentages. EVD, extracardiac vascular disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CAD, coronary artery disease; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; STEMI, ST-segment elevation myocardial infarction; SBP, systolic blood pressure; HR, heart rate; SCr, serum creatinine; eGFR, estimated glomerular filtration rate.

interquartile range,

n = 1049;

n = 1040;

n = 518 (STEMI patients);

primary or non-primary.

The systolic LVF was normal in 30.1%, mildly dysfunctional in 27.9%, moderately dysfunctional in 22% and severely dysfunctional in 20% of the patients who had this measurement done.

Baseline Characteristics and Therapy during the Hospital Stay Comparing AKI to Non-AKI Patients According to the Two AKI Criteria used ([Table 3](#pone-0069998-t003){ref-type="table"}) {#s3b}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Overall, independently of the AKI criteria used, the patients who developed AKI were older and more frequently had a history of hypertension and diabetes than non-AKI patients. A higher proportion of AKI patients were Killip class\>I and had a HR \>100 beat/min at admission than non-AKI subjects. AKI patients received less medical and reperfusion therapy and underwent less invasive procedures than non-AKI patients, but they received more diuretics, and a higher proportion had severe LVD. Patients who developed AKI according to KDIGO had a higher proportion of previous CABG, EVD, and prior use of ACEIs or ARBs than non-AKI patients.

10.1371/journal.pone.0069998.t003

###### Baseline clinical characteristics and medical therapy during hospitalization of AKI versus non-AKI patients according to the two AKI criteria used.
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  Characteristics                                           KDIGO N = 1050   RIFLE N = 1050                                              
  -------------------------------------------------------- ---------------- ---------------- --------- ---------------- ---------------- ---------
  Age \>65 (y)                                                   62.2             45.2        \<0.001        65.2             40.1        \<0.001
  Male                                                           60.9             66.1         0.095         56.1             65.6         0.023
  HTN history                                                    76.6             65.5        \<0.001       78.1%              68          0.012
  Current smoking                                                33.1             39.1         0.043         34.2             37.5         0.425
  Diabetes history                                               33.3              20         \<0.001        37.4             22.7        \<0.001
  HCL history                                                    25.5             20.7         0.073         23.9             22.2         0.652
  EVD history                                                    11.5             5.4         \<0.001        10.3             7.2          0.169
  Prior CAD[\*](#nt111){ref-type="table-fn"}                     15.9             13.5         0.296         14.8             14.3         0.865
  Previous infarction[\*](#nt111){ref-type="table-fn"}           17.2             13.1         0.070         14.8             14.5         0.923
  Previous CABG[\*](#nt111){ref-type="table-fn"}                 10.7             7.1          0.042         8.4              8.4          0.999
  ACEIs/ARBs prior use [†](#nt112){ref-type="table-fn"}          47.6             39.7         0.013         48.1             41.6         0.138
  STEMI[‡](#nt113){ref-type="table-fn"}                          52.9             47.3         0.082         53.5             48.6         0.256
  Killip classes II--IV[‡](#nt113){ref-type="table-fn"}           33              10.5        \<0.001        36.1             16.1        \<0.001
  Anterior wall[‡](#nt113){ref-type="table-fn"}                  31.1              24          0.013         32.9             25.5         0.054
  SBP\<100 (mm Hg)                                               8.3              5.3          0.050         13.5             5.1         \<0.001
  HR \>100 (beats/min)                                           20.6             12.9         0.001         25.2             14.1        \<0.001
  Admission SCr (mg/dL)                                     1.2 (1.0--1.7)   1.2 (1.0--1.4)   \<0.001   1.2 (0.9--1.6)   1.2 (1.0--1.5)    0.940
  eGFR \<60 mL/min/1.73 m^2^                                     53.1             45.9         0.025         52.3             47.9         0.320
  Aspirin                                                        98.7             99.7         0.107         96.8             99.8        \<0.001
  Clopidogrel                                                    81.5             87.1         0.015         75.5             86.7        \<0.001
  β-Blockers                                                     88.8             96.7        \<0.001        83.2             95.6        \<0.001
  ACEIs or ARBs                                                   94              98.5        \<0.001        91.6              98         \<0.001
  Diuretics                                                      77.9             44.1        \<0.001        78.7             52.6        \<0.001
  Coronary angiography                                           72.9             86.8        \<0.001        66.5             84.4        \<0.001
  Any PCI[§](#nt114){ref-type="table-fn"}                        45.1             53.8         0.007         45.8             51.4         0.199
  CABG                                                           5.7              6.6          0.573         3.9              6.7          0.180
  Primary PCI[‡](#nt113){ref-type="table-fn"}                    42.9             58.1         0.001         46.3             53.7         0.221
  Any reperfusion[‡](#nt113){ref-type="table-fn"} ^\|\|^         75.9             83.8         0.025         70.7             83.3         0.007
  Severe LVD[\#](#nt116){ref-type="table-fn"}                    24.4             17.7         0.017         27.2              19          0.04

Continuous variables are presented as medians (with interquartile ranges), and categorical variables are presented as percentages. AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes; HTN, hypertension; HCL, hypercholesterolemia; EVD, extracardiac vascular disease; CAD, coronary artery disease; CABG, coronary artery bypass graft; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; STEMI, ST-segment elevation myocardial infarction; SBP, systolic blood pressure; HR, heart rate; SCr, serum creatinine; eGFR, estimated glomerular filtration rate; PCI, percutaneous coronary intervention; LVD, left ventricular dysfunction.

n = 1049;

n = 1040;

n = 518 (only for STEMI patients);

Primary or non-primary;

with PCI or thrombolytics;

n = 9.

Comparative Incidence, Hospitalization Length and Mortality According to Each Criteria for AKI {#s3c}
----------------------------------------------------------------------------------------------

Incidence and stratification by AKI severity are presented in [Figure 1](#pone-0069998-g001){ref-type="fig"}. The higher AKI incidence found by KDIGO (36.6%) compared with RIFLE (14.8%) was the result of the larger number of patients in KDIGO stage 1 compared with the RIFLE stage Risk (30.8% vs. 9.6%, respectively).

AKI patients diagnosed by RIFLE had a greater median length of hospital stay (8.4 \[interquartile range: 3.6--16.5\] days versus 7.5 \[interquartile range: 4.4--12.6\] days, p\<0.001) than patients without AKI. In the same way, patients diagnosed by KDIGO had greater median length of hospitalization (9.4 \[interquartile range: 4.7--16.2\] days versus 6.7 \[interquartile range: 4.3--11.5\] days, p\<0.001) than subjects without AKI.

AKI patients diagnosed by any AKI criteria had a significantly higher 30-day and 30-days to 1-year mortality rates assessed by univariate analysis than subjects without AKI ([Table 4](#pone-0069998-t004){ref-type="table"}).

10.1371/journal.pone.0069998.t004

###### Univariate analyses for mortality at 30 days and 1-year and comparison between patients who developed and did not develop AKI according to the different AKI definitions.
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  Definition, studied n                                  Mortality         p-value      
  --------------------------------------------------- ---------------- ---------------- ---------
  RIFLE                                                                                 
  30 days (n = 1050)                                   38.1% (59/155)   8.0% (72/895)    \<0.001
  1 year[\*](#nt118){ref-type="table-fn"} (n = 919)     24% (23/96)     10.8% (89/823)   \<0.001
  KDIGO                                                                                 
  30 days (n = 1050)                                   26% (100/384)    4.7% (31/666)    \<0.001
  1 year[\*](#nt118){ref-type="table-fn"} (n = 919)    22.5% (68/336)   7.6% (48/635)    \<0.001
  AKI by KDIGO but not RIFLE                                                            
  30 days **(**n = 895)                                17.9% (41/229)   4.7% (31/666)    \<0.001
  1 year[\*](#nt118){ref-type="table-fn"} (n = 823)    21.9% (41/187)   7.5% (48/636)    \<0.001

AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.

1-year mortality was estimated for those patients who survived after 30 days.

Patients Diagnosed as AKI by KDIGO but not RIFLE Criteria {#s3d}
---------------------------------------------------------

Two hundred twenty-nine patients (21.8% of the entire cohort) were diagnosed as AKI by KDIGO but not by RIFLE. These patients had a greater median length of hospital stay (9.5 \[interquartile range: 5.4--16.0\] days versus 6.7 \[interquartile range: 4.3--11.5\] days, p\<0.001) than patients without AKI by both criteria.

These patients had also a higher 30-day and 30-day to 1-year mortality rates compared with patients who were non-AKI by both criteria ([Table 4](#pone-0069998-t004){ref-type="table"}).

Cox Analyses at 30 days and at 30-day to 1-year {#s3e}
-----------------------------------------------

The development of AKI by RIFLE or KDIGO during hospitalization assessed by Cox analyses remained independently associated with mortality at 30 days and at 30-day to 1-year follow-up. Patients who were diagnosed as AKI by KDIGO but not by RIFLE criteria also had a higher AHR ratio for early and late mortality compared with patients without AKI by any criteria ([Tables 5](#pone-0069998-t005){ref-type="table"} and [6](#pone-0069998-t006){ref-type="table"}; [Figures 2](#pone-0069998-g002){ref-type="fig"}, [3](#pone-0069998-g003){ref-type="fig"} and [4](#pone-0069998-g004){ref-type="fig"}).

![Hazard ratio (Cox multivariate analysis) for death at 30 days and at 30-day to 1-year follow-up according to the different AKI criteria.\
AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.](pone.0069998.g002){#pone-0069998-g002}

![Cox survival curve at 30 days according to the different AKI criteria.\
A. RIFLE; B. KDIGO; C. KDIGO but not RIFLE. AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.](pone.0069998.g003){#pone-0069998-g003}

![Cox survival curve at 30-days to 1-year according to the different AKI criteria.\
A. RIFLE; B. KDIGO; C. KDIGO but not RIFLE. AKI, acute kidney injury; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.](pone.0069998.g004){#pone-0069998-g004}

10.1371/journal.pone.0069998.t005

###### Cox proportional hazard models for the association between 30-day mortality and AKI according to the different AKI criteria used.
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  Criteria for AKI                                         AHR      95% CI     p-value
  ------------------------------------------------------- ------ ------------ ---------
  Patients without AKI[\*](#nt121){ref-type="table-fn"}    1.0                
  RIFLE                                                    3.51   2.35--5.25   \<0.001
  KDIGO                                                    3.99   2.59--6.15   \<0.001
  KDIGO but not RIFLE                                      2.55   1.52--4.28   \<0.001

AKI, acute kidney injury; AHR, adjusted hazard ratio; CI, confidence interval; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.

The model was adjusted for age, gender, admission estimated glomerular filtration rate, history of diabetes, history of extracardiac vascular disease, Killip class, admission systolic blood pressure, admission heart rate, admission creatine phosphokinase and glycemia, clopidogrel use during hospitalization, therapy with diuretics, coronary angiography during hospitalization, reperfusion therapy with primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction, any kind of revascularization with either PCI or coronary artery bypass graft performed during hospitalization, reinfarction or severe systolic left ventricular dysfunction.

The AHR was estimated for each set of criteria with consideration of patients without AKI for each.

10.1371/journal.pone.0069998.t006

###### Cox proportional hazard models for the association between 30-day to 1-year mortality and AKI according to the different AKI criteria used.
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  Criteria for AKI                                         AHR      95% CI     p-value
  ------------------------------------------------------- ------ ------------ ---------
  Patients without AKI[\*](#nt124){ref-type="table-fn"}    1.0                
  RIFLE                                                    1.84   1.12--3.01    0.016
  KDIGO                                                    2.43   1.62--3.62   \<0.001
  KDIGO but not RIFLE                                      2.28   1.46--3.54   \<0.001

AKI, acute kidney injury; AHR, adjusted hazard ratio; CI, confidence interval; RIFLE, Risk, Injury, Failure, Loss, and End-stage kidney Disease; KDIGO, Kidney Disease: Improving Global Outcomes.

The model was adjusted for age, admission estimated glomerular filtration rate, history of hypertension and diabetes, history of extracardiac vascular disease, prior use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, admission Killip class, admission heart rate, admission glycemia, clopidogrel use during hospitalization, therapy with diuretics, coronary angiography during hospitalization, reperfusion therapy with primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction, any type of revascularization with either PCI or coronary artery bypass graft performed during hospitalization or severe systolic left ventricular dysfunction.

The AHR was estimated for each set of criteria, considering patients without AKI for each.

Discussion {#s4}
==========

In the best of our knowledge there are no previous data assessing and comparing AMI-associated AKI diagnosed by RIFLE and KDIGO criteria [@pone.0069998-Rodrigues1]. KDIGO had a higher detection rate for AKI than RIFLE criteria and was the most inclusive criteria. Importantly, patients who were diagnosed as AKI by KDIGO but were missed by RIFLE criteria had a significantly longer hospitalization and a significantly higher AHR for death, which has an obvious clinical implication.

Differences in the AKI Detection Rate by RIFLE Compared with KDIGO {#s4a}
------------------------------------------------------------------

KDIGO diagnosed more AKI than RIFLE during the first seven days of hospitalization. When compared with RIFLE the KDIGO definition diagnosed AKI in an additional 229/1,050 patients, who represented 21.8% of the entire analyzed cohort. If only RIFLE criteria were used, a significant number of patients would be misclassified as non AKI by RIFLE.

The previously reported incidence of AMI-associated AKI is extremely heterogeneous, ranging from 5 to 55% and varies with the criteria used for diagnosing AKI and the studied clinical setting [@pone.0069998-Bruetto1]--[@pone.0069998-Amin2], [@pone.0069998-Hwang1], [@pone.0069998-Mielniczuk1]. These large disagreements in the incidence of AKI among previous studies reflect the lack of standardization for diagnosing AKI and support the need for a defined and validated set of AKI criteria instead of arbitrary definitions.

In this study we have used only the SCr criteria for diagnosing and staging AKI by RIFLE definition, although the original criteria also used GFR decreases for AKI diagnosis and staging [@pone.0069998-Bellomo1]. In fact, the use of GFR criteria calculated as 25% decrease for risk and as 75% decrease for failure stages has been questioned since in steady-state the 1.5-fold increase in SCr would correspond to a one-third decrease (instead of 25%) in GFR and the 3-fold increase in SCr would correspond to a two-thirds decrease (instead of 75%) in GFR [@pone.0069998-Pickering1]. Moreover, GFR is seldom measured in the context of AKI, but estimated by formulas using SCr measurements. Nevertheless, estimation of GFR by formulas is only valid when SCr is in equilibrium, which is not the case for AKI.

We also decided not to use the urinary output criteria, since they are less validated, may be influenced by several drugs used by this studied population and are very difficult to capture and measure reliably in the emergency room setting.

Why is the AKI Detection Rate Higher with KDIGO than RIFLE? {#s4b}
-----------------------------------------------------------

The most relevant difference between KDIGO and RIFLE is related to the conditions necessary to classify a patient as KDIGO stage 1 or RIFLE stage Risk. Whereas a SCr increase of ≥50% from baseline is necessary in RIFLE, by the KDIGO definition, only an absolute SCr increase of 0.3 mg/dL (≥26.5 µmol/L) within 48 hours is sufficient for an AKI diagnosis. The 0.3 mg/dL variation was included in the KDIGO definition because such small changes in SCr have been independently associated with death in AKI patients [@pone.0069998-Lassnigg1], [@pone.0069998-Praught1]. Small changes in SCr have also been associated with early and long-term mortality in cohorts of AMI patients [@pone.0069998-Newsome1], [@pone.0069998-Parikh1].

A potential problem with the use of a moving 48 h window for AKI diagnosis, as recommended by KDIGO and AKIN definitions, is when SCr decreases in comparison with the pre-event value due to fluid accumulation with a subsequent increase of at least 0.3 mg/dL. In a study on AKI after cardiopulmonary bypass the authors found significantly more patients diagnosed as AKI by AKIN (26.3%) than by RIFLE (18.9%) criteria (p\<0.0001). Patients classified as AKI in one but not in the other definition set were predominantly staged in the lowest AKI severity class (9.6% of patients in AKIN stage 1 and 2.3% of patients in RIFLE class R). The authors determined that the differences between patients diagnosed as AKI by RIFLE or AKIN were mainly found in the subgroup that had an initial decrease of SCr from preoperative baseline to post-operatory day 1, probably due to fluid accumulation during surgery. In this subgroup, post-operative SCr values that were lower than preoperative levels served as comparison in the 48-hour moving diagnostic window of AKIN [@pone.0069998-Englberger1]. That is not the case for the current study since patients after AMI are not massively hydrated as during cardiopulmonary bypass, and consequently the AMI patients assessed are certainly less affected by a dilution of the baseline SCr. Although our data are favorable for the use of the KDIGO criteria, the reference SCr possibly needs to be differently defined depending on the particular studied population, and in some circumstances the pre-event baseline SCr could be more reliable for AKI diagnosis than the moving 48 hour SCr window.

Mortality {#s4c}
---------

After controlling for the prognostic variables that might affect mortality after STEMI and NSTEMI, AKI diagnosed by both criteria remained independently associated with mortality at 30-days and 1-year follow-up.

The most important novel finding of the current study is that patients with an AKI diagnosis by KDIGO, but not by RIFLE, had a higher AHR for mortality when compared with non-AKI patients. These results indicate that a large number of patients with AMI-induced AKI and elevated risk for mortality would be missed by the RIFLE criteria.

Study Limitations {#s4d}
-----------------

This was an observational single-center prospective cohort study.

A possible study limitation is related to the time of the assessment of the reference SCr level. This limitation occurred due to difficulties to obtain reference SCr data prior to the event precipitating admission, as most patients have not undergone a previous renal function evaluation prior to their hospital entry for an acute illness as AMI. Various strategies for dealing with pre-event absent reference SCr have been highlighted, such as using lowest admission or discharge SCr against which to diagnose AKI [@pone.0069998-Endre1]. In the current study we have chosen to use the admission SCr as the reference value used to diagnose AKI. As a result, it is possible that some patients who were hospitalized already had AKI, but because the SCr did not increase further, they were misclassified as non-AKI. In the same way, patients who present with renal dysfunction at admission and theirs SCr did not decrease after admission actually might have suffered an AKI just before the hospitalization. In fact, a recent study on cardiac arrest patients requiring resuscitation suggested that patients whose SCr did not decrease after admission in that scenario, actually did have AKI [@pone.0069998-Pickering2].

Conclusions {#s5}
===========

KDIGO had a higher detection rate for AKI than RIFLE. Patients misclassified as non-AKI by RIFLE had a higher AHR for death when compared with non-AKI subjects according to any definition. As a more inclusive criterion, KDIGO is probably more suitable for AKI diagnosis and risk stratification in patients with AMI.
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